Effects of Esketamine on inflammatory mediators, postoperative depression-like mood and intestinal flora in patients undergoing radical operation for lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070910

Enrollment

Unknown

Registered

2023-04-26

Start date

2023-03-28

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

group E:Intravenous esketamine

group C:Intravenous saline

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with radical resection of lung cancer; 2. Gender limitation; 3. Aged 18-65 years; 4. ASA Grade ?-?.

Exclusion criteria

Exclusion criteria: 1. Severe uncontrolled hypertension (SBP=180mmHg or DBP=110mmgHg); 2. Neuropsychiatric diseases; 3. Inability to understand or use VAS pain scores; 4. Unable to understand or use the PHQ9 depression scale score; 5. Esketamine drug allergy.

Design outcomes

Primary

Measure	Time frame
PHQ9 scales;Intestinal flora;	—

Secondary

Measure	Time frame
Visual Analog Scale (VAS);inflammatory;	—

Countries

china

Contacts

Public ContactZhoujun

the Affiliated Hospital of Southwest Medical University

47147381@qq.com+86 18715816677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026